Why is the BARD1 Life Sciences (ASX:BD1) share price rocketing 78%?

The BARD1 Life Sciences share price is up an eye-popping 78% in early afternoon trading. We look at what's driving ASX investor interest.

The BARD1 Life Sciences Ltd (ASX: BD1) share price is up an eye-popping 66% at the time of writing. That's down a bit from gains of more than 87% in early morning trade.

Investor interest appears to be driven by the company's positive announcement on its ovarian cancer test. Let's take a closer look at the announcement and what it means for the BARD1 share price.

woman in lab coat conducting testing.

Image source: Getty Images

What did BARD1 report on its cancer test?

BARD1 released a report to the ASX this morning stating that it's SubB2M technology is able to detect all stages of ovarian cancer.  The data was collected from Griffith University's Institute of Glycomics. It indicates the technology is able to do this with 100% specificity and 100% sensitivity.

SubB2M is a protein that binds to a sugar molecule called Neu5Gc. This protein is present in a range of cancers. The company reported that researchers from the University of Adelaide and Griffith University have proven its ability to detect Neu5Gc in cancer patients' bloodstreams.

BARD1 holds the exclusive worldwide license for the use of SubB2M to detect any cancer.

Dr. Lucy Shewell from Griffith University's Institute for Glycomics concluded that detection of Neu5Gc-glycans using SubB2M can potentially be used as a diagnostic marker to detect early-stage ovarian cancer. She said it may also be a useful tool to monitor disease progression in late-stage cancer.

Comments from the CEO

Addressing the positive results, BARD1's CEO, Dr. Leearne Hinch, said:

The company is focused on early detection of cancer and our SubB2M technology provides the potential for developing tests for monitoring and detection of multiple cancers. We will continue to collaborate with Griffith University to develop and validate commercial assays for monitoring treatment response and recurrence in ovarian cancer patients to improve health outcomes for this critical unmet medical need.

The company also stated that ovarian cancer remains the leading cause of gynaecological cancer deaths worldwide. This statement highlights the potential benefits of its SubB2M test. In 2018 there were 185,000 deaths from ovarian cancer. Ovarian cancer often progresses to a late-stage before diagnosis. This means the current 5-year survival rate is only 46%.

BARD1 share price snapshot

The BARD1 share price has a lengthy history of volatility, even without the 49% share price crash during last autumn's COVID-driven market rout. With today's intraday gains factored in, the BARD1 share price is up 88% in 2021.

By comparison, the All Ordinaries Index (ASX: XAO) is up just over 2%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Opinions

3 reasons why I think this leading ASX 200 share is a buy

This underrated business could be a top buy today…

Read more »

Man in shirt and tie falls face first down stairs.
Record Lows

I think this ASX 200 stock looks like a bargain after hitting an all-time low: Here's why

The ASX shares fell another 8% on Tuesday.

Read more »

A woman looks excited as she fans out a wad of Aussie $100 notes.
Broker Notes

Macquarie predicts 90% upside and an 8% dividend yield for this ASX share

If the broker is right, this share will pay off nicely.

Read more »

Man working on a laptop from home.
ASX Share Market News

5 things to watch on the ASX 200 on Wednesday

It could be another tough session for Aussie investors on hump day.

Read more »

A woman sprints with a trail of fire blazing from her body.
Opinions

I hunted the ASX for shares with the potential to double. This one stood out

Do you have this ASX share in your investment portfolio?

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Opinions

I wanted growth, not hype. Only 3 ASX shares passed my checks

One of these ASX shares is tipped to climb up to 38%.

Read more »